Segall Bryant & Hamill LLC lifted its position in NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 11.6% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,113,822 shares of the medical research company's stock after purchasing an additional 220,415 shares during the period. Segall Bryant & Hamill LLC owned 1.65% of NeoGenomics worth $34,836,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently bought and sold shares of NEO. SBI Securities Co. Ltd. bought a new position in shares of NeoGenomics during the 4th quarter worth $26,000. Versant Capital Management Inc raised its position in shares of NeoGenomics by 174.9% in the 4th quarter. Versant Capital Management Inc now owns 1,795 shares of the medical research company's stock worth $30,000 after acquiring an additional 1,142 shares in the last quarter. Quarry LP purchased a new stake in shares of NeoGenomics during the 3rd quarter worth $40,000. Smartleaf Asset Management LLC boosted its position in NeoGenomics by 203.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 4,156 shares of the medical research company's stock valued at $70,000 after purchasing an additional 2,787 shares in the last quarter. Finally, Blue Trust Inc. boosted its holdings in shares of NeoGenomics by 33.2% in the 4th quarter. Blue Trust Inc. now owns 4,421 shares of the medical research company's stock valued at $73,000 after buying an additional 1,103 shares in the last quarter. Institutional investors own 98.50% of the company's stock.
NeoGenomics Stock Performance
NeoGenomics stock traded up $0.14 during trading hours on Friday, hitting $9.62. 1,995,897 shares of the stock traded hands, compared to its average volume of 880,633. The firm's 50 day moving average price is $11.92 and its 200-day moving average price is $14.36. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.98 and a quick ratio of 1.91. The stock has a market capitalization of $1.24 billion, a price-to-earnings ratio of -15.52 and a beta of 1.28. NeoGenomics, Inc. has a 1 year low of $8.98 and a 1 year high of $19.12.
NeoGenomics (NASDAQ:NEO - Get Free Report) last issued its earnings results on Tuesday, February 18th. The medical research company reported ($0.02) EPS for the quarter, missing analysts' consensus estimates of $0.03 by ($0.05). NeoGenomics had a negative net margin of 11.92% and a negative return on equity of 2.10%. The firm had revenue of $172.00 million during the quarter, compared to analysts' expectations of $173.40 million. As a group, equities analysts expect that NeoGenomics, Inc. will post -0.2 EPS for the current fiscal year.
Analyst Ratings Changes
Several research analysts recently commented on NEO shares. Benchmark lowered shares of NeoGenomics from a "buy" rating to a "hold" rating in a research note on Monday, January 13th. Jefferies Financial Group initiated coverage on shares of NeoGenomics in a report on Tuesday, December 10th. They issued a "buy" rating and a $22.00 price target on the stock. The Goldman Sachs Group decreased their price objective on NeoGenomics from $20.00 to $18.00 and set a "buy" rating for the company in a report on Tuesday, January 28th. Piper Sandler lowered their price objective on NeoGenomics from $21.00 to $18.00 and set an "overweight" rating for the company in a research report on Wednesday, February 26th. Finally, Needham & Company LLC reduced their target price on NeoGenomics from $19.00 to $18.00 and set a "buy" rating on the stock in a research report on Wednesday, February 19th. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, NeoGenomics presently has an average rating of "Moderate Buy" and an average price target of $19.60.
Read Our Latest Analysis on NeoGenomics
About NeoGenomics
(
Free Report)
NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.
See Also
Before you consider NeoGenomics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NeoGenomics wasn't on the list.
While NeoGenomics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market volatility creates opportunity. Our analysts have pinpointed 10 stocks perfectly positioned for exceptional growth this spring, even amid economic uncertainty. Don't miss your chance to access this timely research and invest with confidence.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
